Gardnerella Vaginalis: Characteristics, Clinical Considerations, and Controversies B
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
BD™ Gardnerella Selective Agar with 5% Human Blood
INSTRUCTIONS FOR USE – READY-TO-USE PLATED MEDIA PA-254094.06 Rev.: July 2014 BD Gardnerella Selective Agar with 5% Human Blood INTENDED USE BD Gardnerella Selective Agar with 5% Human Blood is a partially selective and differential medium for the isolation of Gardnerella vaginalis from clinical specimens. PRINCIPLES AND EXPLANATION OF THE PROCEDURE Microbiological method. Gardnerella vaginalis is considered to be one of the organisms causing vaginitis.1-4 Although the organism may be present in a high percentage of normal women in the vaginal flora, its importance as a cause of non-specific vaginitis (also called bacterial vaginosis) has never been questioned. In symptomatic women, G. vaginalis frequently is associated with anaerobes such as Prevotella bivia, P. disiens, Mobiluncus, Peptostreptococcus, and/or others which are a regular part of the urethral or intestinal, but not vaginal flora. In non-specific vaginitis, normal Lactobacillus flora is reduced or absent. Gardnerella vaginalis is considered to be the indicator organism for non-specific vaginitis which, in fact, is a polymicrobial infection.3,4 Although non- culture methods such as a direct Gram stain have been recommended in recent years for genital specimens, culture is still preferred by many laboratories.1,5 G. vaginalis may also be responsible for a variety of other diseases such as preterm birth, chorioamnionitis, urinary tract infections, newborn infections, and septicemia.6 The detection of the organism on routinely used media is difficult since Gardnerella and other -
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine -
Human Microbiota Network: Unveiling Potential Crosstalk Between the Different Microbiota Ecosystems and Their Role in Health and Disease
nutrients Review Human Microbiota Network: Unveiling Potential Crosstalk between the Different Microbiota Ecosystems and Their Role in Health and Disease Jose E. Martínez †, Augusto Vargas † , Tania Pérez-Sánchez , Ignacio J. Encío , Miriam Cabello-Olmo * and Miguel Barajas * Biochemistry Area, Department of Health Science, Public University of Navarre, 31008 Pamplona, Spain; [email protected] (J.E.M.); [email protected] (A.V.); [email protected] (T.P.-S.); [email protected] (I.J.E.) * Correspondence: [email protected] (M.C.-O.); [email protected] (M.B.) † These authors contributed equally to this work. Abstract: The human body is host to a large number of microorganisms which conform the human microbiota, that is known to play an important role in health and disease. Although most of the microorganisms that coexist with us are located in the gut, microbial cells present in other locations (like skin, respiratory tract, genitourinary tract, and the vaginal zone in women) also play a significant role regulating host health. The fact that there are different kinds of microbiota in different body areas does not mean they are independent. It is plausible that connection exist, and different studies have shown that the microbiota present in different zones of the human body has the capability of communicating through secondary metabolites. In this sense, dysbiosis in one body compartment Citation: Martínez, J.E.; Vargas, A.; may negatively affect distal areas and contribute to the development of diseases. Accordingly, it Pérez-Sánchez, T.; Encío, I.J.; could be hypothesized that the whole set of microbial cells that inhabit the human body form a Cabello-Olmo, M.; Barajas, M. -
Use of Nifuratel to Treat Infections Caused by Atopobium Species
(19) & (11) EP 2 243 482 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.10.2010 Bulletin 2010/43 A61K 31/422 (2006.01) A61P 15/02 (2006.01) A61P 31/04 (2006.01) A61P 13/02 (2006.01) (2006.01) (21) Application number: 09158221.3 A61P 15/00 (22) Date of filing: 20.04.2009 (84) Designated Contracting States: (72) Inventor: Mailland, Federico AT BE BG CH CY CZ DE DK EE ES FI FR GB GR CH-6900 Lugano (CH) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR (74) Representative: Pistolesi, Roberto et al Designated Extension States: Dragotti & Associati Srl AL BA RS Via Marina 6 20121 Milano (IT) (71) Applicant: Polichem SA 1526 Luxembourg (LU) (54) Use of nifuratel to treat infections caused by atopobium species (57) The present invention is directed to the use of genitalia in both sexes, as well as bacterial vaginosis, or nifuratel, or a physiologically acceptable salt thereof, to mixed vaginal infections in women, when one or more treat infections caused by Atopobium species. The in- species of the genus Atopobium are among the causative vention is further directed to the use of nifuratel to treat pathogens of those infections. bacteriuria, urinary tract infections, infections of external EP 2 243 482 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 243 482 A1 Description [0001] The present invention relates to the use of nifuratel, or a physiologically acceptable salt thereof, to treat infections caused by Atopobium species. -
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
JET Microbiological Efficacy Summary
Microbiological Efficacy Summary Testing performed in accordance to European Standard EN 14885:2018 ORGANISM TEST NORM TEST TYPE CONDITIONS Bacillus subtilis EN 13704 Suspension Clean 1 and Dirty 1 Bacillus cereus SPORICIDAL Mycobacterium terrae EN 14563 Carrier Clean 1 and Dirty 2 Mycobacterium avium Mycobacterium terrae EN 14348 Suspension Clean 1 Mycobacterium avium MYCOBACTERICIDAL Poliovirus Type 1 Adenovirus Type 5 EN 14476 Suspension Clean 1 Murine Norovirus VIRUCIDAL Candida albicans EN 16615 Surface with mechanical action Candida albicans EN 13697 Surface Aspergillus brasiliensis EN 14562 Carrier Clean 1 Candida albicans YEASTICIDAL FUNGICIDAL / FUNGICIDAL Aspergillus brasiliensis EN 13624 Suspension Candida albicans Staphylococcus aureus Enterococcus hirae EN 16615 Surface with mechanical action Pseudomonas aeruginosa Enterococcus hirae Staphylococcus aureus EN 13697 Surface Clean 1 Pseudomonas aeruginosa Escherichia coli Staphylococcus aureus BACTERICIDAL Enterococcus hirae EN 14561 Carrier Pseudomonas aeruginosa Staphylococcus aureus Enterococcus hirae EN 13727 Suspension Clean 1 and Dirty 1 Pseudomonas aeruginosa TRISTEL’S CLEANING AND DISINFECTION BRAND FOR HOSPITAL SURFACES Page 1 of 3 Additional Testing TEST METHOD RNA DNA / Polyacrylamide gel electrophoresis (PAGE) ORGANISM TEST METHOD TEST TYPE CONDITIONS Acanthamoeba castellanii cysts Following the method of EN 13704 Suspension Clean 1 PROTOZOA Bacillus subtilis EN 17126 Suspension Clean 1 Bacillus cereus Clostridium difficile EN 13704 Suspension Clean 1 and Dirty 1 -
NOTES in Vitro Activities of Norfloxacin and Ciprofloxacin Against
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1984, p. 94-96 Vol. 26, No. 1 0066-4804/84/070094-03$02.00/0 Copyright C 1984, American Society for Microbiology NOTES In Vitro Activities of Norfloxacin and Ciprofloxacin Against Mycobacterium tuberculosis, M. avium Complex, M. chelonei, M. fortuitum, and M. kansasii J. DOUGLAS GAY, DONALD R. DEYOUNG, AND GLENN D. ROBERTS* Section of Clinical Microbiology, Department of Laboratory Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905 Received 28 November 1983/Accepted 4 April 1984 The activities of ciprofloxacin and norfloxacin against 100 mycobacteria isolates were studied in vitro by the 1% standard proportion method. Ciprofloxacin was more active against M. tuberculosis and M. fortuitum with MICs of 1.0 and 0.25 ,ug/ml, respectively, against 90% of isolates; norfloxacin had MICs of 8.0 and 2.0 ,ug/ml, respectively, against 90% of isolates. Nalidixic acid and other heterocyclic carbonic acid deriva- studied. The organisms were taken from the Mayo Clinic tives have been used primarily in the treatment of urinary stock culture collection, which included recent clinical iso- tract infections for many years. The compounds of this lates. Stock cultures were maintained on Middlebrook 7H10 general group include nalidixic acid, oxolinic acid, pipemidic agar slants (Difco Laboratories, Detroit, Mich.) and were acid, cinoxacin, and rosoxacin. Two new substances in this subcultured monthly. The identification of isolates was series which have been recently synthesized are norfloxacin based on standard biochemical tests (17) and gas-liquid (6) (1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[ 1-piperazinyl ]-3- chromatography (16). -
A Genomic Journey Through a Genus of Large DNA Viruses
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Virology Papers Virology, Nebraska Center for 2013 Towards defining the chloroviruses: a genomic journey through a genus of large DNA viruses Adrien Jeanniard Aix-Marseille Université David D. Dunigan University of Nebraska-Lincoln, [email protected] James Gurnon University of Nebraska-Lincoln, [email protected] Irina V. Agarkova University of Nebraska-Lincoln, [email protected] Ming Kang University of Nebraska-Lincoln, [email protected] See next page for additional authors Follow this and additional works at: https://digitalcommons.unl.edu/virologypub Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Cell and Developmental Biology Commons, Genetics and Genomics Commons, Infectious Disease Commons, Medical Immunology Commons, Medical Pathology Commons, and the Virology Commons Jeanniard, Adrien; Dunigan, David D.; Gurnon, James; Agarkova, Irina V.; Kang, Ming; Vitek, Jason; Duncan, Garry; McClung, O William; Larsen, Megan; Claverie, Jean-Michel; Van Etten, James L.; and Blanc, Guillaume, "Towards defining the chloroviruses: a genomic journey through a genus of large DNA viruses" (2013). Virology Papers. 245. https://digitalcommons.unl.edu/virologypub/245 This Article is brought to you for free and open access by the Virology, Nebraska Center for at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Virology Papers by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Authors Adrien Jeanniard, David D. Dunigan, James Gurnon, Irina V. Agarkova, Ming Kang, Jason Vitek, Garry Duncan, O William McClung, Megan Larsen, Jean-Michel Claverie, James L. Van Etten, and Guillaume Blanc This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/ virologypub/245 Jeanniard, Dunigan, Gurnon, Agarkova, Kang, Vitek, Duncan, McClung, Larsen, Claverie, Van Etten & Blanc in BMC Genomics (2013) 14. -
Sample Report Vaginosis.Pdf
LAB #: Sample Report CLIENT #: 12345 PATIENT: Sample Patient DOCTOR: Sample Doctor ID: Doctor's Data, Inc. SEX: Female 3755 Illinois Ave. DOB: 01/01/1993 AGE: 25 St. Charles, IL 60174 U.S.A. !"#$%&'(%(!)*'+%,- GRAM STAIN MICROSCOPY BACTERIAL VAGINOSIS SCORE Normal Abnormal Expected score interpretation: Lactobacilli None Mod - Many 0 - 3 BV not likely 4 - 6 BV indeterminate Curved Gram 10 7-10 BV highly suggestive Negative Rods Many None Small Gram 1 Many None The BV score is calculated based upon the gram stain results Negative Rods and is independent of the yeast, and bacterial cultures. 1Nugent Scoring System. (Nugent et al. J. Clin. Micro. Yeast None None (1991)29:297-301) RBC’s None None YEAST CULTURE 2+ Candida albicans WBC’s 0 0 - 6 Clue Cells Present None Eosinophils N/A None Eosinophils reported and Wrights Stain performed when WBC’s >6 Additional Gram Stain Findings: Rare Gram positive cocci in pairs BACTERIOLOGY CULTURE Expected/Beneficial flora Commensal (Imbalanced) flora Dysbiotic flora NG Lactobacillus spp. 2+ Alpha hemolytic strep 3+ Gardnerella vaginalis 2+ Gamma hemolytic strep 4+ Enterococcus faecalis 1+ Staphylococcus not aureus NG = No Growth SPECIMEN DATA Comments: Date Collected: 01/14/2019 Date Received: 01/16/2019 Date Completed: 01/23/2019 ©Doctor’s Data, Inc. !!! ADDRESS: 3755 Illinois Avenue, St. Charles, IL 60174-2420 !!! MED DIR: Erlo Roth, MD !!! CLIA ID NO: 14D0646470 0002038 LAB #: Sample Report CLIENT #: 12345 PATIENT: Sample DOCTOR: Sample Doctor Patient ID: Doctor's Data, Inc. SEX: Female 3755 Illinois Ave. DOB: 01/01/1993 St. Charles, IL 60174 U.S.A. -
PDF Library/Candidiasis.Pdf 7 Sexually Transmitted Diseases Treatment Guidelines, 2010
COMMISSION DE LA TRANSPARENCE Avis 2 octobre 2013 FLUCONAZOLE MAJORELLE 150 mg, gélule B/1 (34009 395 173 0 8) Laboratoire MAJORELLE DCI fluconazole Code ATC (2012) J02AC01 (Antimycosiques à usage systémique) Motif de l’examen Inscription Liste(s) Sécurité Sociale (CSS L.162-17) concernée(s) Collectivités (CSP L.5123-2) Indication(s) « Traitement des Candidoses vaginales et périnéales aiguës et concernée(s) récidivantes » HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique 1/12 Avis 1 modifié le 28 novembre 2014 SMR SMR modéré ASMR ASMR de niveau V Place dans la Le traitement des candidoses vaginales et périnéales aiguës et récidivantes , stratégie peut être local ou systémique. Dans le cas d’un traitement systémique, il thérapeutique s’agit d’un traitement en dose unique. HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique 2/12 Avis 1 modifié le 28 novembre 2014 01 INFORMATIONS ADMINISTRATIVES ET REGLEMENTAIRES AMM 24/07/2009 (procédure nationale) Conditions de prescription et de Liste I délivrance / statut particulier 2012 J Anti-infectieux généraux à usage systémique J02 Antimycosiques à usage systémique Classification ATC J02A Antimycosiques à usage systémique J02AC Dérivés triazolés J02AC01 Fluconazole 02 CONTEXTE Il s’agit d’une demande d’inscription de la spécialité FLUCONAZOLE MAJORELLE 150 mg en gélule, sur la liste des spécialités remboursables aux assurés sociaux et sur la liste des médicaments agrées à l’usage des collectivités. FLUCONAZOLE MAJORELLE 150 mg est un générique de la spécialité princeps FLUCONAZOLE PFIZER 150 mg. Il existe deux autres spécialités génériques, BEAGYNE 150 mg et FLUCONAZOLE SANDOZ 150 mg. -
Mycobacterium Avium Possesses Extracellular DNA That Contributes to Biofilm Formation, Structural Integrity, and Tolerance to Antibiotics
Mycobacterium avium Possesses Extracellular DNA that Contributes to Biofilm Formation, Structural Integrity, and Tolerance to Antibiotics Rose, S. J., Babrak, L. M., & Bermudez, L. E. (2015). Mycobacterium avium Possesses Extracellular DNA that Contributes to Biofilm Formation, Structural Integrity, and Tolerance to Antibiotics. PLoS ONE, 10(5), e0128772. doi: 10.1371/journal.pone.0128772 10.1371/journal.pone.0128772 Public Library of Science Version of Record http://cdss.library.oregonstate.edu/sa-termsofuse RESEARCH ARTICLE Mycobacterium avium Possesses Extracellular DNA that Contributes to Biofilm Formation, Structural Integrity, and Tolerance to Antibiotics Sasha J. Rose1,2, Lmar M. Babrak1,2, Luiz E. Bermudez1,2* 1 Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, United States of America, 2 Department of Microbiology, College of Science, Oregon State University, Corvallis, Oregon, United States of America * [email protected] Abstract Mycobacterium avium subsp. hominissuis is an opportunistic pathogen that is associated with biofilm-related infections of the respiratory tract and is difficult to treat. In recent years, extracellular DNA (eDNA) has been found to be a major component of bacterial biofilms, in- OPEN ACCESS cluding many pathogens involved in biofilm-associated infections. To date, eDNA has not Citation: Rose SJ, Babrak LM, Bermudez LE (2015) been described as a component of mycobacterial biofilms. In this study, we identified and Mycobacterium avium Possesses Extracellular DNA characterized eDNA in a high biofilm-producing strain of Mycobacterium avium subsp. that Contributes to Biofilm Formation, Structural hominissuis (MAH). In addition, we surveyed for presence of eDNA in various MAH strains Integrity, and Tolerance to Antibiotics. -
Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01